2 news items
Ipsen And Sutro Biopharma Enter Exclusive Global Licensing Agreement For An ADC Targeting Solid Tumors
STRO
2 Apr 24
shown robust monotherapy efficacy and potential for a differentiated safety profile in preclinical development in solid tumors and hematological malignancies1
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
STRO
2 Apr 24
monotherapy efficacy and potential for a differentiated safety profile in preclinical development in solid tumors and hematological
- Prev
- 1
- Next